Label: Information for the User
Ziagen 300mg Film-Coated Tablets
abacavir
Read this label carefully before starting to take this medicine, because it contains important information for you.
IMPORTANT — Hypersensitivity Reactions
Ziagen contains abacavir(which is also the active ingredient in medicines such asKivexa, TriumeqandTrizivir). Some people who take abacavir may develop ahypersensitivity reaction(severe allergic reaction), which can be life-threatening if they continue to take medicines containing abacavir.
You must carefully read the information about “Hypersensitivity Reactions” in section 4 of this label.
The Ziagen packaging includes aInformation Cardto remind you and healthcare professionals of your hypersensitivity to abacavir.You must remove this card and carry it with you at all times.
1.What is Ziagen and what is it used for
2.What you need to knowbefore starting to take Ziagen
3.How to take Ziagen
4.Possible side effects
5.Storage of Ziagen
6.Contents of the pack and additional information
Ziagen is used in the treatment of infection caused by the HIV (human immunodeficiency virus).
Ziagen contains abacavir as its active ingredient. Abacavir belongs to a group of antiretroviral medications calledinhibitors of reverse transcriptase analogs of nucleosides(NRTIs).
Ziagen does not completely cure HIV infection; it reduces the amount of virus in the body and keeps it at a low level. It also increases the number of CD4 cells in the blood. CD4 cellsare a type of white blood cell that plays an important role in helping your body fight infection.
Not everyone responds to Ziagen treatment in the same way. Your doctor will monitor the effectiveness of your treatment.
Read carefully all the information about hypersensitivity reactions in section 4 of this leaflet.
Consult your doctorif you think you are affected by any of these circumstances.
Be especially careful with Ziagen
Some people taking Ziagen for HIV have a higher risk of severe side effects. You need to know that there is a higher risk:
Consult your doctor ifyou suffer from any of these circumstances.You may need additional tests, including blood tests, while taking this medicine.For more information see section 4.
Hypersensitivity reactions to abacavir
Even patients who do not have the HLA-B*5701 gene can developa hypersensitivity reaction(a severe allergic reaction).
Read carefully all the information about hypersensitivity reactions in section 4 of this leaflet.
Risk of cardiovascular events
It cannot be ruled out that abacavir increases the risk of cardiovascular events.
Inform your doctorif you have cardiovascular problems, if you smoke or if you suffer from diseases that may increase the risk of cardiovascular diseases, such as high blood pressure or diabetes. Do not stop taking Ziagen unless your doctor advises you to.
Be aware of important symptoms
Some people taking HIV medicines develop other diseases, which can be serious. You need to know what signs and symptoms to look out for while taking Ziagen.
Read the information about “Other possible side effects of HIV combination treatment” in section 4 of this leaflet.
Other medicines and Ziagen
Inform your doctor or pharmacist if you aretakingor have recently takenother medicines,including herbal medicines and those bought without a prescription.Remember to inform your doctor or pharmacist if you start taking a new medicine while taking Ziagen.
Some medicines interact with Ziagen
These include:
Inform your doctorif you are taking phenytoin. Your doctor may need to monitor you while you are taking Ziagen.
Informyour doctorif you are taking methadone.
Pregnancy
Ziagen is not recommended during pregnancy. Ziagen and similar medicines may cause adverse effects in babies during pregnancy.If you have been takingZiagenduring your pregnancy, your doctor may request that you have regular blood tests and other diagnostic tests to monitor the development of your baby. In children whose mothers took INTIs during pregnancy, the benefit of HIV protection was greater than the risk of adverse effects.
Breastfeeding
It is not recommendedthat women with HIV breastfeed because HIV infection can be transmitted to the baby through breast milk. A small amount of the components of Ziagen may also pass into breast milk.
If you are breastfeeding or plan to breastfeed,you should consult your doctor as soon as possible.
Driving and operating machines
Do not drive or operate machinesunless you are feeling well.
Important information about some of the components of Ziagen tablets
This medicine contains less than 1 mmol of sodium (23 mg) per dose unit; this is, essentially “sodium-free”.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Swallow the tablets with a little water. Ziagen can be taken with or without food.
If you cannot swallow the tablets whole, you can break them and mix them with a small amount of food or drink; take the entire dose immediately.
Maintain regular contact with your doctor
Ziagen helps control your condition. You will need to take it every day to prevent your disease from worsening. You may continue to develop other infections and diseases associated with HIV infection.
Remain in contact with your doctor and do not stop taking Ziagenwithout first speaking with your doctor.
How much to take
Adults, adolescents, and children weighing at least 25 kg:
The usual dose of Ziagen is 600 mg per day. It can be taken as one 300 mg tablet twice a day, or two 300 mg tablets once a day.
Children from one year of age weighing less than 25 kg
The dose depends on the child's body weight. The recommended dose is:
The tablet can be divided into equal doses.
A oral solution (20 mg of abacavir/ml) is available for the treatment of children over three months and weighing less than 14 kg, as well as for patients who require a reduction in the usual dose or who are unable to take tablets.
If you take more Ziagen than you should
If you accidentally take more Ziagen than you should, inform your doctor or pharmacist, or contact the nearest hospital emergency service for more information.
If you forgot to take Ziagen
If you forget to take a dose, take it as soon as you remember and then continue with your usual treatment.
Do not take a double dose to compensate for the missed doses.
It is essential to take Ziagen regularly, as irregular intake of Ziagen may increase the risk of experiencing a hypersensitivity reaction.
If you have interrupted treatment with Ziagen
If for any reason, you have stopped taking Ziagen — especially because you think it has side effects or due to another illness:
Consult your doctor before resuming treatment. Your doctor will check if your symptoms were related to a hypersensitivity reaction. If your doctor considers that there may be a relationship,he will instruct you thatyou should never take Ziagen again or any other medication that contains abacavir (e.g. Triumeq, Trizivir, or Kivexa).It is essential that you follow this warning.
If your doctor advises you to resume treatment with Ziagen, you can ask him to take the first doses in a place where you have easy access to medical assistance if necessary.
During treatment for HIV, there may be an increase in weight and levels of glucose and lipids in the blood. This may be partly related to recovery of health and lifestyle, and in the case of lipids in the blood, sometimes to the HIV medications themselves. Your doctor will monitor these changes.
Like all medications, this medication can produce side effects, although not everyone will experience them.
When you are being treated for HIV, it can be difficult to distinguish whether a symptom is a side effect of Ziagen or of other medications you are taking, or is due to an effect of the disease caused by HIV.Therefore, it is very important that you inform your doctor about any change in your health.
Even patients who do not have the HLA-B*5701 gene can developasevere hypersensitivity reaction(a severe allergic reaction), described in this leaflet in the box called “Hypersensitivity reactions”.
It is very important that you read and understand the information about this severe reaction.
In addition to the side effects listed below for Ziagen, other disorders can develop during combined HIV treatment.
It is important that you read the information under the heading “Other possible side effects of combined HIV treatment”.
Hypersensitivity reactions
Ziagencontainsabacavir(active ingredient also present inTrizivir, TriumeqandKivexa).
Abacavir can produce a severe allergic reaction known as a hypersensitivity reaction. These hypersensitivity reactions have been observed more frequently in people taking medications containing abacavir.
Who suffers these reactions?
Any person taking Ziagen could develop a hypersensitivity reaction to abacavir,which could put their life at risk if they continue taking Ziagen.
You are more likely to develop this reaction if you have a gene calledHLA-B*5701(but you can still suffer this reaction even if you do not have this gene). Before starting treatment with Ziagen, you should have had a test to detect this gene.If you know you have this gene, tell your doctor before taking Ziagen.
About3 to4 out of every 100 patients, treated with abacavir in a clinical trial, who did not have the HLA-B*5701 gene, developedahypersensitivity reaction.
What are the symptoms?
The most common symptoms are:
•fever(high temperature) andskin rash.
Other frequently observed signs include:
•nausea(unpleasant feeling), vomiting, diarrhea, abdominal pain (stomach) and excessive fatigue.
Other symptoms may include:
Joint or muscle pain, swelling of the neck, difficulty breathing, sore throat, occasional headache, conjunctivitis (inflammation in the eye), mouth ulcers, low blood pressure and tingling or numbness in the hands or feet.
When do these reactions occur?
Hypersensitivity reactions can occur at any time during treatment with Ziagen, but it is more likely to happen in the first 6 weeks of treatment.
If you are caring for a child who is being treated with Ziagen, it is essential that you understand the information about this hypersensitivity reaction. If the child experiences the symptoms described belowfollow the instructions indicated.
Contact your doctor immediately:
1if you have a skin rash
2if you have symptoms included in at least 2 of the following groups:
- fever
- difficulty breathing, sore throat or cough
-nausea or vomiting, diarrhea or abdominal pain
-excessive fatigue or general discomfort.
Your doctor may advise you to stop taking Ziagen.
While taking Ziagen, always carry the Patient Information Leaflet with you.
If you have stopped taking Ziagen
If you have stopped taking Ziagen due to a hypersensitivity reaction,NEVER TAKE Ziagen or any other medication containing abacavir (e.g. Trizivir, Triumeq or Kivexa) again.If you do, within hours, you may experience a drop in blood pressure that can put your life at risk or cause death.
If for any reason, you have interrupted treatment with Ziagen — especially because you think you are experiencing side effects or another illness:
Consult your doctor before resuming treatment.
Your doctor will check if your symptoms were related to a hypersensitivity reaction. If your doctor considers that there may have been a relationship,they will advise youthat you should never take Ziagen or any other medication containing abacavir (e.g. Trizivir, Triumeq or Kivexa) again.It is essential that you follow this warning.
Sometimes, hypersensitivity reactions have developed in people who have taken abacavir again after having had only one symptom from the list in the Patient Information Leaflet before they stopped taking it.
Rarely, patients who have taken medications containing abacavir in the past without experiencing hypersensitivity symptoms have developed a hypersensitivity reaction when they took it again.
If your doctor advises you to restart treatment with Ziagen, you can ask them to take the first two doses in a place where you have easy access to medical assistance if necessary.
If you are hypersensitive to Ziagen, you must return all your Ziagen tablets without using them, so they can be disposed of safely.Consult your doctor or pharmacist.
The Ziagen packaging includes aPatient Information Leafletto remind you and healthcare staff about hypersensitivity reactions.Separate the leaflet from the packaging and carry it with you always.
Common side effects
May affectup to 1 in 10people:
Rare side effects
May affectup to 1 in 1,000people:
Very rare side effects
May affectup to 1 in 10,000people:
If you notice any of these symptoms, contact a doctor urgently.
If you experience side effects
Consult your doctor or pharmacistif you experience side effects,including possible side effects that do not appear in this leaflet.You can also report them directly through the national notification system included in theAppendixV. By reporting side effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box.The expiration date is the last day of the month indicated.
Do not store at a temperature above30°C.
Medicines should not be disposed of through drains or in the trash.Ask your pharmacist how to dispose ofthe packaging and the medications that you no longerneed.This will help protect the environment.
The active ingredient of each scored tablet of Ziagen is 300 mg of abacavir (as sulfate).
The other components are microcrystalline cellulose, carboxymethylstarch sodium, magnesium stearate, and anhydrous colloidal silica in the tablet core. The coating contains triacetin, hypromellose (E464), titanium dioxide (E171), polysorbate 80 (E433), and yellow iron oxide.
Appearance of Ziagen and contents of the pack
The scored tablets of Ziagen are engraved on both sides with “GX 623”. They are yellow, capsule-shaped, and are presented in blister packs containing 60 tablets.
Marketing Authorisation Holder
ViiV Healthcare BV, Van Asch van Wijckstraat 55H, 3811 LP Amersfoort, Netherlands
Manufacturer(s)
Delpharm Poznan Spólka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland.
For more information about this medicinal product, please contact the local representative of the marketing authorisation holder.
België/Belgique/Belgien ViiV Healthcare srl/bv Tél/Tel:+ 32 (0) 10 85 65 00 | Lietuva ViiV Healthcare BV Tel: + 37080000334 |
ViiV Healthcare BV Te?.: +359 80018205 | Luxembourg/Luxemburg ViiV Healthcare srl/bv Belgique/Belgien Tél/Tel:+ 32 (0) 10 85 65 00 |
Ceská republika GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 | Magyarország ViiV Healthcare BV Tel.: + 3680088309 |
Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com | Malta ViiV Healthcare BV Tel: + 35680065004 |
Deutschland ViiV Healthcare GmbH Tel.:+ 49 (0)89203 0038-10 | Nederland ViiV Healthcare BV Tel: + 31 (0)33 2081199 |
Eesti ViiV Healthcare BV Tel: + 3728002640 | Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Ελλ?δα GlaxoSmithKlineΜονοπρ?σωπηA.E.B.E. Τηλ: + 30 210 68 82 100 | Österreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 |
España Laboratorios ViiV Healthcare, S.L. Tel: +34 900 923 501 | Polska GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9000 |
France ViiV Healthcare SAS Tél.: + 33 (0)1 39 176969 Hrvatska ViiV Healthcare BV Tel: + 385800787089 | Portugal VIIVHIVHEALTHCARE, UNIPESSOAL, LDA Tel: + 351 21094 08 01 România ViiV Healthcare BV Tel: +40800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenija ViiV Healthcare BV Tel: + 38680688869 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika ViiV Healthcare BV Tel: + 421800500589 |
Italia ViiV Healthcare S.r.l Tel: + 39 (0)45 7741600 | Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 |
Κ?προς ViiV Healthcare BV Τηλ:+ 35780070017 | Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 |
Latvija ViiV Healthcare BV Tel: + 37180205045 | United Kingdom (Northern Ireland) ViiV Healthcare BV Tel: + 44 (0)800 221441 |
Fecha de la última revisión de este prospecto: |
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu/.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.